doi: 10.3389/fphar.2026.1805842 Received 06 February 2026 Revised 30 March 2026 Accepted 06 April 2026 Published 29 April 2026 Volume 17 - 2026 Edited by Brian J Piper, Center for Pharmacy Innovation and Outcomes, United States Reviewed by Kenneth McCall, Binghamton University, United States Santenna Chenchula, All India Institute of Medical Sciences, India Youssef Soliman, Wright State University, United States Updates Copyright 2026 Zinzi, Gaio, Ruggiero, Mascolo, Riemma, Cipriani, Laino, Berrino, Rossi and Capuano
Aflatoxins and growth impairment: a review
Physiological diversity of mitochondrial oxidative phosphorylation
With the approval of Wegovy for MASH, we provide a new treatment to people living with MASH that not only halts the disease activity but helps reverse the damage caused to the liver. As of today, Wegovy is available in the US for the treatment for MASH